首页> 美国卫生研究院文献>Aging (Albany NY) >LKB1 inactivation leads to centromere defects and genome instability via p53-dependent upregulation of survivin
【2h】

LKB1 inactivation leads to centromere defects and genome instability via p53-dependent upregulation of survivin

机译:LKB1失活导致Centromere缺陷和基因组不稳定性通过P53依赖性上调的Survivin

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inactivating mutations in the liver kinase B1 (LKB1) tumor suppressor gene underlie Peutz-Jeghers syndrome (PJS) and occur frequently in various human cancers. We previously showed that LKB1 regulates centrosome duplication via PLK1. Here, we report that LKB1 further helps to maintain genomic stability through negative regulation of survivin, a member of the chromosomal passenger complex (CPC) that mediates CPC targeting to the centromere. We found that loss of LKB1 led to accumulation of misaligned and lagging chromosomes at metaphase and anaphase and increased the appearance of multi- and micro-nucleated cells. Ectopic LKB1 expression reduced these features and improved mitotic fidelity in LKB1-deficient cells. Through pharmacological and genetic manipulations, we showed that LKB1-mediated repression of survivin is independent of AMPK, but requires p53. Consistent with the key influence of LKB1 on survivin expression, immunohistochemical analysis indicated that survivin is highly expressed in intestinal polyps from a PJS patient. Lastly, we reaffirm a potential therapeutic avenue to treat LKB1-mutated tumors by demonstrating the increased sensitivity to survivin inhibitors of LKB1-deficient cells.
机译:在肝激酶B1(LKB1)肿瘤抑制基因下培育族综合征(PJS)中的灭活突变在各种人类癌症中经常发生。我们之前表明LKB1通过PLK1调节了Centrosome重复。在这里,我们认为LKB1进一步有助于通过Survivin的阴性调节来维持基因组稳定性,染色体乘客综合体(CPC)的成员介导靶向CENTROMERE。我们发现LKB1的损失导致中期和后脱离的未对准和滞后染色体的积聚,并增加了多核和微核细胞的外观。异位LKB1表达减少了这些特征,并改善了LKB1缺陷细胞中的有丝分裂保真度。通过药理学和遗传操作,我们表明LKB1介导的Survivin的抑制与AMPK无关,但需要p53。与LKB1对Survivin表达的关键影响一致,免疫组织化学分析表明,Survivin在来自PJS患者的肠息肉中高度表达。最后,我们通过证明对LKB1缺陷细胞的Survivin抑制剂的敏感性增加,重申潜在的治疗途径来治疗LKB1突变的肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号